PL366397A1 - Zastosowanie szczepów owczego parapoksywirusa do wytwarzania przeciwwirusowych i przeciwnowotworowych środków farmaceutycznych - Google Patents

Zastosowanie szczepów owczego parapoksywirusa do wytwarzania przeciwwirusowych i przeciwnowotworowych środków farmaceutycznych

Info

Publication number
PL366397A1
PL366397A1 PL01366397A PL36639701A PL366397A1 PL 366397 A1 PL366397 A1 PL 366397A1 PL 01366397 A PL01366397 A PL 01366397A PL 36639701 A PL36639701 A PL 36639701A PL 366397 A1 PL366397 A1 PL 366397A1
Authority
PL
Poland
Prior art keywords
antiviral
production
antitumor
pharmaceuticals
strains
Prior art date
Application number
PL01366397A
Other languages
English (en)
Inventor
Olaf Weber
Tobias Schlapp
Angela Siegling
Andreas Knorr
Claudia Hirth-Dietrich
Gudrun Theiss
Hans-Dieter Volk
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122451A external-priority patent/DE10122451A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of PL366397A1 publication Critical patent/PL366397A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL01366397A 2000-07-11 2001-07-11 Zastosowanie szczepów owczego parapoksywirusa do wytwarzania przeciwwirusowych i przeciwnowotworowych środków farmaceutycznych PL366397A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033582 2000-07-11
DE10122451A DE10122451A1 (de) 2000-07-11 2001-05-09 Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs

Publications (1)

Publication Number Publication Date
PL366397A1 true PL366397A1 (pl) 2005-01-24

Family

ID=26006335

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366397A PL366397A1 (pl) 2000-07-11 2001-07-11 Zastosowanie szczepów owczego parapoksywirusa do wytwarzania przeciwwirusowych i przeciwnowotworowych środków farmaceutycznych

Country Status (36)

Country Link
US (1) US6685950B2 (pl)
EP (1) EP1303286B1 (pl)
JP (1) JP5037775B2 (pl)
CN (1) CN1455674B (pl)
AR (1) AR029954A1 (pl)
AT (1) ATE324115T1 (pl)
AU (2) AU7063101A (pl)
BG (1) BG107448A (pl)
CA (1) CA2415397C (pl)
CY (1) CY1105408T1 (pl)
CZ (1) CZ200371A3 (pl)
DE (1) DE50109630D1 (pl)
DK (2) DK1303286T3 (pl)
EE (1) EE200300018A (pl)
ES (1) ES2262663T3 (pl)
FI (1) FI20030037L (pl)
GB (1) GB2381454B8 (pl)
HK (1) HK1054329B (pl)
HR (1) HRP20030096A2 (pl)
HU (1) HUP0400479A3 (pl)
IL (1) IL153643A0 (pl)
LT (1) LT5079B (pl)
LU (1) LU90997B1 (pl)
LV (1) LV12990B (pl)
MA (1) MA26927A1 (pl)
MX (1) MXPA03000279A (pl)
NO (1) NO20030082D0 (pl)
NZ (1) NZ523534A (pl)
PL (1) PL366397A1 (pl)
PT (1) PT1303286E (pl)
RU (1) RU2003104525A (pl)
SE (1) SE0300034L (pl)
SI (1) SI21122A (pl)
SK (1) SK362003A3 (pl)
UY (1) UY26832A1 (pl)
WO (1) WO2002004002A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
WO2002042480A2 (en) * 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
NZ512341A (en) * 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
EP1499355A4 (en) * 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
SG173216A1 (en) * 2002-04-19 2011-08-29 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates
UA85543C2 (ru) * 2002-09-05 2009-02-10 Бавариан Нордик А/С Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
ATE442155T1 (de) 2004-07-13 2009-09-15 Aicuris Gmbh & Co Kg Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
PL1951274T3 (pl) * 2005-11-24 2010-05-31 Aicuris Gmbh & Co Kg Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka
JP5004990B2 (ja) * 2009-03-31 2012-08-22 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
CA2783510C (en) * 2009-12-18 2019-01-08 Bavarian Nordic A/S Production of ifn-lambda by conventional dendritic cells and uses thereof
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
DE3504940C2 (de) * 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
AU718141B2 (en) * 1996-02-28 2000-04-06 Bayer Healthcare Ag Parapoxviruses which contain foreign DNA, their preparation and their use in vaccines
EP0904393A4 (en) * 1996-03-29 1999-09-08 Univ Otago PARAPOXVIRUS VECTORS
ES2125846T3 (es) * 1996-04-15 2001-12-16 Anton Prof Dr Med Vet Dr Mayr Nuevas indicaciones para el empleo de inductores de parainmunidad multipotentes a partir de virus de viruela o virus de paraviruela atenuados, no inmunogenos, como medicamento.
SE9700617D0 (sv) * 1997-02-21 1997-02-21 Kjell Alving New composition
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
DE69931178T8 (de) * 1998-11-02 2007-06-28 Ludwig Institute For Cancer Research Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2

Also Published As

Publication number Publication date
LV12990B (en) 2003-08-20
US6685950B2 (en) 2004-02-03
SK362003A3 (en) 2003-07-01
LT2003009A (en) 2003-08-25
HUP0400479A3 (en) 2006-02-28
LT5079B (lt) 2003-12-29
RU2003104525A (ru) 2004-06-27
EP1303286B1 (de) 2006-04-26
WO2002004002A2 (de) 2002-01-17
DK200300015A (da) 2003-03-07
CN1455674A (zh) 2003-11-12
IL153643A0 (en) 2003-07-06
LU90997B1 (en) 2003-01-08
SI21122A (sl) 2003-08-31
HRP20030096A2 (en) 2005-02-28
PT1303286E (pt) 2006-08-31
CA2415397A1 (en) 2002-01-17
DK1303286T3 (da) 2006-08-28
WO2002004002A3 (de) 2002-10-31
GB2381454B (en) 2004-11-24
UY26832A1 (es) 2002-01-31
ATE324115T1 (de) 2006-05-15
CA2415397C (en) 2011-04-26
GB2381454A8 (en) 2007-10-23
HK1054329A1 (en) 2003-11-28
SE0300034L (sv) 2003-03-03
HUP0400479A2 (hu) 2004-06-28
MA26927A1 (fr) 2004-12-20
AU2001270631B2 (en) 2005-07-07
EP1303286A2 (de) 2003-04-23
SE0300034D0 (sv) 2003-01-10
GB0302630D0 (en) 2003-03-12
GB2381454B8 (en) 2007-10-23
JP5037775B2 (ja) 2012-10-03
BG107448A (bg) 2003-11-28
NZ523534A (en) 2005-02-25
NO20030082L (no) 2003-01-08
AU7063101A (en) 2002-01-21
FI20030037A7 (fi) 2003-03-10
EE200300018A (et) 2004-10-15
NO20030082D0 (no) 2003-01-08
DE50109630D1 (de) 2006-06-01
FI20030037L (fi) 2003-03-10
US20030021769A1 (en) 2003-01-30
CN1455674B (zh) 2019-03-29
AR029954A1 (es) 2003-07-23
HK1054329B (zh) 2005-10-07
JP2004517807A (ja) 2004-06-17
CZ200371A3 (cs) 2003-04-16
ES2262663T3 (es) 2006-12-01
GB2381454A (en) 2003-05-07
CY1105408T1 (el) 2010-04-28
MXPA03000279A (es) 2004-04-05

Similar Documents

Publication Publication Date Title
PL366397A1 (pl) Zastosowanie szczepów owczego parapoksywirusa do wytwarzania przeciwwirusowych i przeciwnowotworowych środków farmaceutycznych
PT1095025E (pt) Benzimidazoles sua producao e sua utilizacao como medicamentos
GB2397488B (en) Absorbent personal care article with fastening system
IL168102A0 (en) Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
DE10197409A5 (de) Verringerung der gegenseitigen Störung von drahtlosen Systemen
AU2001282449A8 (en) Applications of the biofeedback technique
ATE314072T1 (de) Antivirale azaindolderivate
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
EE200200607A (et) 2-atsüülindoolderivaadid ja nende kasutamine kasvajavastaste ravimitena
EP1299337A4 (en) HYDROXYPHENSTATIN AND ITS PROMEDICATIONS
ID26612A (id) Turunan-turunan siklobutena, pembuatannya dan penggunaan-penggunaan terapinya
IS2174B (is) Setnar fenýl-píperasín afleiður, framleiðsla þeirra og notkun
NO994730D0 (no) Vognkarosseri med rammeverk
PT1387838E (pt) Derivados de cianoantranilamida e sua utilizacao como farmaco
ATA184999A (de) Geteilter dorn
DE60119813D1 (de) Raupe und dessen Herstellungsverfahren
ATE374011T1 (de) Hautbehandlungsmittel
DE60118910D1 (de) Phosphatkonversionsüberzugverfahren und zusammensetzung
DE50104256D1 (de) Walzwerk
FI20011710L (fi) Menetelmä rullan siirtämiseksi ja rullain
AR028398A1 (es) Ciclipostinas, procedimiento para su preparacion, y utilizacion de las mismas
PT1373249E (pt) Derivados de imidazolidina, sua preparacao e sua utilizacao como agente anti-inflamatorio
DE60226371D1 (de) Druckmaschine und Drucksystem
FR2814920B1 (fr) Bagage roulant
GB2377950B (en) Structural framework, method of forming the framework and webs therefor

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)